UNSPSC 51334406: Diclometide

This classification denotes an antipsychotic agent with the molecular formula C14H20Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05186J17EP, chemically known as 3,5-dichloro-n-(2-(diethylamino)-ethyl)-o-anisamide. but generally known as diclometide, which bears US NIH Compound Identifier 208832. European Medicines Agency schedules Diclometide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07096MIG.

UNSPSC 51334406 Diclometide is a Commodity code with minimal recent state and local procurement activity. The single recent opportunity posted under this code — Seminole County, Florida's IFB 60459723LAS for naloxone and drug deactivation systems — does not align with the code's nominal pharmaceutical scope. Seminole County's June 30, 2026 posting seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs, submit bids electronically, and comply with drug-free workplace certification, E-Verify requirements, and insurance coverage mandates including workers' compensation and commercial general liability. The procurement includes a two-year initial term with a one-year renewal option and carries a three-month probationary period with potential termination at the county's discretion.

The code shows activity only in Florida, with Seminole County as the identified issuing body. The July 26, 2023 response deadline in the opportunity record conflicts with the June 30, 2026 posting date, suggesting a data inconsistency in the source material. Beyond this single opportunity, no recent state or local solicitations under UNSPSC 51334406 are documented, indicating that the code does not currently reflect active procurement demand across state and local jurisdictions. Firms pursuing opportunities in pharmaceutical procurement or emergency response supply chains should monitor the code for activity, but present signals do not support an aggressive pursuit strategy.